Blockchain Registration Transaction Record

NRx Pharmaceuticals Challenges FDA to Remove Toxic Additive from Ketamine Products

NRx Pharmaceuticals petitions FDA to remove toxic BZT from ketamine products, advocating for safer treatments for suicidal depression and PTSD. Learn more.

This news is crucial for patients and healthcare providers as it highlights the potential risks associated with current ketamine treatments and the push for safer alternatives. The removal of BZT from ketamine products could significantly reduce side effects and improve patient outcomes, especially for those battling severe conditions like suicidal depression and PTSD. NRx Pharmaceuticals' initiative represents a pivotal moment in the biopharmaceutical industry's ongoing efforts to ensure drug safety and efficacy.